4
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Power of plasma N-terminal proatrial natriuretic factor to determine haemodynamics in patients with cardiac disease: relation to serum creatinine

, , &
Pages 395-404 | Published online: 08 Jul 2009

REFERENCES

  • Raine AE, Erne P, Bfirgisser E, Muller FB, Bolli P, Burkhart F, et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med 1986; 315: 533–7.
  • Edwards BS, Zimmerman RS, Schwab TR, Denise MH, Burnett JC Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic peptide. Circ Res 1988; 62: 191 — 5.
  • Weidmann P, Hasler L, Gnädinger MP, Lang RE, Uehlinger DE, Shaw S, et al. Blood levels and renal effects of atrial natriuretic peptide in normal man. J Clin Invest 1986; 77: 734–42.
  • Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986; 78: 1362–74.
  • Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espinger EA, Livesey JH. Metabolic clearance rate and plasma half life of alfa-human atrial natriuretic peptide in man. Life Sci 1986; 38: 1827 — 33.
  • Nelesen RA, Dimsdale JE, Ziegler MG. Plasma atrial natriuretic peptide is unstable under most storage conditions. Circulation 1992; 86: 463 — 6.
  • Thibault G, Murthy KK, Gutkowska J, Siedah NG, Lazure C, Chretien M, et al. NH2-terminal fragment of rat pro-atrial natriuretic factor in the circulation: identification, radioimmunoassay and half-life. Peptides 1988; 9: 47 — 53.
  • Sundsfjord JA, Thibault G, Larochelle P, Cantin M. Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab 1988; 66: 605 — 10.
  • Mathisen P, Hall C, Simonsen S. Comparative study of atrial peptides ANP (1— 98) and ANP (99 — 126) as diagnostic markers of atrial distension in patients with cardiac disease. Scand J Clin Lab Invest 1993; 53: 41 — 9.
  • Winters CJ, Sallman AL, Baker BJ, Meadows J, Rico DM, Vesely DL. The N-terminus and a 4,000-MW peptide from the midportion of the N-terminus of the atrial natriuretic factor pro-hormone each circulate in humans and increase in congestive heart failure. Circulation 1989; 80: 438 —49.
  • Lerman A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinley LJ, Heublein DM, et al. Circulating N- terminal atrial natriuretic peptide as a marker for symptomless left ventricular dysfunction. Lancet 1993; 341: 1105–9.
  • Remes J, Miettinen H, Reunanen A, Pyörälä K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991; 12: 315 — 21.
  • Wheeldon NM, MacDonald TM, Flucker CJ, McKendrick AD, McDevitt DG, Struthers AD. Echocardiography in chronic heart failure in the community. Q J Med 1993; 86: 17 — 23.
  • Choy AM, Darbar D, Lang CC, Pringle TH, McNeill GP, Kennedy NS, et al. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardio-graphic, and neurohormonal methods. Br Heart J 1994; 72: 16 — 22.
  • Hall C, Kjekshus J, Eneroth P, Snapinn S. The plasma concentration of N-terminal proatrial natriuretic factor ANP(1 —98) is related to prog-nosis in severe heart failure. Clin Cardiol 1994; 17: 191 — 5.
  • Hall C, Rouleau JL, Moy6 L, Lemuel M, de Champlain J, Bichet D, etal. N — terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation 1994; 89: 1934–42.
  • Dickstein K, Aarsland T, Hall C. Plasma N-term-inal atrial natriuretic factor: a predictor of survival in patients with congestive heart failure. J Cardiac Failure 1997; 3: 83–9.
  • The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricu-lar ejection fractions. N Engl J Med 1992; 327: 685— 91.
  • Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarc-tion. Results of the survival and ventricular enlar-gement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669–77.
  • Winters CJ, Vesely DL. Change in plasma immu-noreactive N-terminus, C-terminus, and 4,000 dal-ton midportion of atrial natriuretic factor prohormone with hemodialysis. Nephron 1991; 58: 17— 22.
  • Buckley MG, Sagnella GA, Markandu ND, Singer DRJ, MacGregor GA. Immunoreactive N-term-inal pro-atrial natriuretic peptide in human plasma: plasma levels and comparisons with a-human atrial natriuretic peptide in normal subjects, patients with essential hypertension, cardiac trans-plant and chronic renal failure. Clin Sci 1989; 77: 573–9.
  • Grossman W, Baim DS. Cardiac catheterization, angiography, and intervention. 4th ed. London: Lea & Febiger, 1991.
  • Hosmer DW, Lemeshow S. Applied logistic regres-sion. New York: John Wiley, 1989.
  • Kleinbaum DG, Kupper LL, Muller KE. Applied regression analysis and other multivariate meth-ods. Boston. PWS — KENT, 2nd ed. 1987: 316 — 37.
  • Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29— 36.
  • Armitage P, Berry G. Statistical methods in medi-cal research. 2nd ed. Oxford: Blackwell, 1987.
  • Marshall WJ. Illustrated textbook or clinical chem-istry. London: Gower, 1988.
  • Bonarjee VV, Omland T, Nilsen DW, Caidahl K, Sundsfjord JA, Dickstein K. Plasma proatrial natriuretic factor (1 —98) concentration after myo-cardial infarction: relation to indices of cardiac and renal function. Br Heart J 1995; 73: 511 —6.
  • Davidson NC, Abdelwahab AN, Hanson JK, Kennedy NSJ, Coutie WJ, Struthers AD. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996; 77: 828— 31.
  • Katsube N, Schwartz D, Needleman P. Atriopeptin turnover: quantitative relationship between in vivo changes in plasma levels and atrial content. J Phar-macol Exp Ther 1986; 239: 474–9.
  • Sakai T, Latson TW, Whitten CW, O'Flaherty DN, Vu D, Krishnan S, et al. Changes in plasma atrial natriuretic peptide concentration during heart transplantation. J Cardiothorac Vasc Anesth 1992; 6: 686 —91.
  • Holmström H, Thaulow E, Stokke 0, Lindberg H, Hall C. Serum N-terminal proatrial natriuretic factor in children with congenital heart disease. Eur Heart J 1996; 17: 1737–46.
  • Omland T, Aakvaag A, Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild ven-tricular impairment. Heart 1996; 76: 232–7.
  • Cowie MR, Struthers AD, Wood DA, Coats AJS, Thomson SG, Poole-Wilson PA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1347–51.
  • McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detec-tion of left-ventricular systolic dysfunction. Lancet 1998; 351: 9–13.
  • Rodeheffer RJ, Naruse M, Atkinson JB, Naruse K, Burnett JC Jr, Merill WH, etal. Molecular forms of atrial natriuretic factor in normal and failing human myocardium. Circulation 1993; 88: 364–71.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.